TNXP · Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals announced a commercial payer coverage agreement with a leading group purchasing organization (GPO) for TONMYA, its recently approved fibromyalgia treatment. The agreement, effective May 1, 2026, provides access to approximately 35 million U.S. commercial lives, representing about 20% of the total U.S. commercial market. This milestone is significant for Tonix as it expands patient access to TONMYA, which was FDA-approved in August 2025 and commercially launched in November 2025. The company also noted that TONMYA is currently covered under Medicaid in 38 states, covering approximately 55 million beneficiaries. Management expressed optimism about this first managed care partnership and intends to pursue additional coverage across commercial and government channels, including Medicare and Medicaid. The agreement includes standard utilization management criteria, and Tonix offers a patient support program to assist with access. This development is a positive step for Tonix's commercial strategy, potentially driving prescription volumes and revenue growth for TONMYA.